Sanofi, an R&D-driven and AI-powered biopharmaceutical company, has announced plans to implement a share buyback programme worth up to Euro 1 billion in 2026. The move reflects the company’s ongoing commitment to disciplined capital allocation while maintaining focus on innovation-led growth.

On February 2, 2026, Sanofi entered into a mandate agreement with an investment service provider to execute the programme. Under the terms of the mandate, the company will repurchase its own shares for a total consideration of up to Euro 1 billion. The buyback will be carried out between February 3, 2026, and December 31, 2026, at the latest.

Sanofi continues to position itself as a science-led global biopharma company leveraging artificial intelligence and deep immunology expertise to develop transformative medicines and vaccines.